Sustained-release bupropion in the treatment of SSRI nonresponder pathologic gamblers: Pilot study and review of the literature

Therapy

Volumn 2, Issue 5, 2005, Pages 753-757

  Dannon, Pinhas N ^a   Lowengrub, Katherine ^a   Musin, Ernest ^a   Gonopolski, Yehudit ^a   Kotler, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Addictive disorder; Bupropion sustained release; Impulsive behavior; Pathologic gambling; Selective serotonin reuptake inhibitors

Indexed keywords

AMFEBUTAMONE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HUMAN; MALE; PATHOLOGICAL GAMBLING; PILOT STUDY; PSYCHIATRIC DIAGNOSIS; QUESTIONNAIRE; REMISSION; REVIEW; SEIZURE; SELF REPORT; SINGLE BLIND PROCEDURE; SUSTAINED RELEASE FORMULATION; SYMPTOMATOLOGY; VERTIGO;

EID: 26844465133     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.2.5.753     Document Type: Review

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, WA, USA (1994).
2. World Health Organization. ICD-10 Classification of Mental & Behavioural Disorders. World Health Organization, Geneva, Switzerland (1992).
3. Volberg PA. The prevalence and demographics of Pathologic gamblers: implications for public health. Am. J. Pub. Health 84, 237-241 (1994).
4. Adlaf, EM., Ialomiteanu, A. Prevalence of problem gambling in adolescents: findings from the 1999 Ontario Student Drug Use Survey. Can. J. Psychiat. 45, 752-755 (1999).
5. Chambers RA, Potenza MN. Neurodevelopment, impulsivity, and adolescent gambling. J. Gambling Studies 19(1), 53-84 (2003).
6. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of Pathologic gambling. Curr. Psychiat. Rep. 5, 9-15 (2003).
7. Hollander E, Pallanti S, Allen A et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in Pathologic gamblers with bipolar spectrum disorders? Am. J. Psychiat. 162, 137-145 (2005).
8. McElroy SL, Pope HG, Keck PE et al. Are impulse-control disorders related to bipolar disorder? Comp. Psychiat. 37, 229-240 (1996).
9. Hollander E, Wong CM. Introduction: obsessive-compulsive spectrum disorder. J. Clin. Psychiat. 56(Suppl. 4), 3-6 (1995).
10. Blanco C, Moreyra P, Nunes EV, Saiz-Ruiz J, Ibanez A. Pathologic gambling: addiction or compulsion? Semin. Clin. Neuropsychiat. 6, 167-176 (2001).
11. Brady KT, Myrick H, McElroy S. The relationship between substance use disorders, impulse-control disorders, and Pathologic aggression. Am. J. Addict. 7, 221-230 (1998).
12. Kim SW, Grant, JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of Pathologic gambling. Bio. Psychiat. 49, 914-921 (2001).
13. Belson MG, Kelly TR. Bupropion exposures: Clinical manifestations and medical outcome. Emerg. Med. 23, 223-230 (2002).
14. Sullivan MA, Covey LS. Nicotine dependence: the role for antidepressants and anxiolytics. Curr. Opin. Invest. Drugs 3, 262-271 (2002).
15. Sullivan MA, Covey LS. Nicotine dependence: the role for antidepressants and anxiolytics. Curr. Opin. Invest. Drugs 3, 262-271 (2002).
16. Hamilton M. The assessment of anxiety states by rating. British J. Med. Psycho. 32, 50-59 (1959).
17. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiat. 23, 56-62 (1960).
18. Guy W. Early Clinical Drug Evaluation Unit Assessment Manual for Psychopharmacology. Deptartment of Health, Education & Welfare, WA, USA (1976).
19. Leisure HR., Blume S. The south oaks gambling screen: a new instrument for the identification of Pathologic gamblers. Am. J. Psychiat. 144, 1184-1188 (1987).
20. Black D. An open-label trial of bupropion in the treatment of Pathologic gambling. J. Clin. Psychopharmacol. 24, 108-109 (2004).
21. Dannon PN. Preliminary findings on the use of buproprion for pathologic gambling. Presented at: The American Psychiatric Association NY, USA (2001).
22. Hollander E, Decaria CM, Finkell JN. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Bio. Psychiat. 47, 813-817 (2000).
23. Hollander E, DeCaria CM, Mari E. Short-term single-blind fluvoxamine treatment of Pathologic gambling. Am. J. Psychiat. 155, 1781-1783 (1998).
24. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of Pathologic gambling. J. Clin. Psychiat. 63, 44-48 (2002).
25. McElroy SL, Pope HG, Keck PE et al. Are impulse-control disorders related to bipolar disorder? Comp. Psychiat. 37, 229-240 (1996).
26. Grant JE, Potenza MN. impulse-control disorders: clinical characteristics and pharmacological management. Ann. Clin. Psychiat. 16, 27-34 (2004).
27. Grant JE, Kim SW, Potenza MN et al. Paroxetine treatment of Pathologic gambling: a multi-centre randomized controlled trial. Int. Clin. Psychopharmacol. 18, 243-249 (2003).
28. Hollander E, Benzaquen SD. Is there a distinct OCD Spectrum? CNS Spectrums 1, 17-26 (1996).
29. Ibanez A, Blanco C, Donahue E et al. Psychiatric comorbidity in Pathologic gamblers seeking treatment. Am. J. Psychiat. 158, 1733-1735 (2001).
30. Potenza MN. Neurobiology of Pathologic gambling. Semin. Clin. Neuropsychiat. 6, 217-226 (2001).
31. Belson MG, Kelly TR. Bupropion exposures: Clinical manifestations and medical outcome. Emerg. Med. 23, 223-230 (2002).
32. Anton RF. Pharmacologic approaches to the management of alcoholism. J. Clin. Psychol. 62(Suppl. 20) 11-17 (2001).
33. Volpicelli JR, Pettinati HM et al. Naltrexone and alcohol dependence. Arch. Gen. Psychiat. 54, 737-742 (1997).
34. Zbikowski SM, Swan GE, McClure JB. Cigarette smoking and nicotine dependence. Med. Clinics North Am. 8 8, 1453-1465 (2004).
35. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention deficit/hyperactivity disorder. J. Addict. Dis. 21, 1-16 (2002).
36. Chan-Ob T, Kuntawongse N, Boonyanaruthee V. Bupropion for amphetamine withdrawal syndrome. J. Med. Assoc. Thailand 84, 1763-1765. (2001).
37. Tardieu S, Poirier Y, Micallef J, Blin O. Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. Acta Psychiat. Scand. 109, 75-77 (2004).
38. Kim SW, Grant JE., Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of Pathologic gambling. Bio. Psychiat. 49, 914-921 (2001).
39. Zwar N, Richmond R. Bupropion Sustained Release. A therapeutic review of Zyban. Aus. Fam. Physician 31, 443-447 (2002).
40. Steel Z, Blaszczynski A. Impulsivity, personality disorders, and Pathologic gambling severity. Addiction 93, 895-905 (1998).